Abstract | AIMS: METHODS AND RESULTS: Baseline neutrophil count was measured in 2865 patients in CLARITY-TIMI 28, a randomized trial of clopidogrel vs. placebo in STEMI patients undergoing fibrinolysis. Angiography was performed at 2-8 days following enrollment. Analyses were adjusted for demographics, time from symptom onset, Killip class, peak CK-MB, and therapies received. A baseline neutrophil count in the highest quartile was independently associated with the risk of cardiovascular (CV) death [adj (adjusted) OR (odds ratio) 5.8, P < 0.001] and congestive heart failure (adj OR 3.0, P = 0.009) at 30 days. Patients with higher neutrophil counts were less likely to achieve complete ST-segment resolution (adj OR 0.76, P = 0.03) or TIMI myocardial perfusion grade 2/3 (adj OR 0.71, P = 0.017). Clopidogrel had a lesser effect on reducing the odds of a closed infarct-related artery, or death or MI before angiography, in patients with a neutrophil count above the median (adjusted OR 0.83, 0.61-1.13) vs. in those below the median (adjusted OR 0.46, 0.33-0.64) (Pinteraction = 0.008). CONCLUSION: In patients with STEMI, higher baseline neutrophil count is associated with worse angiographic findings and increased CV mortality, as well as a diminished benefit of clopidogrel.
|
Authors | Michelle O'Donoghue, David A Morrow, Christopher P Cannon, Wei Guo, Sabina A Murphy, C Michael Gibson, Marc S Sabatine |
Journal | European heart journal
(Eur Heart J)
Vol. 29
Issue 8
Pg. 984-91
(Apr 2008)
ISSN: 0195-668X [Print] England |
PMID | 18346960
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Platelet Aggregation Inhibitors
- Clopidogrel
- Ticlopidine
|
Topics |
- Clopidogrel
- Coronary Angiography
- Epidemiologic Methods
- Female
- Humans
- Leukocyte Count
- Male
- Middle Aged
- Myocardial Infarction
(diagnostic imaging, drug therapy, mortality)
- Neutrophils
- Platelet Aggregation Inhibitors
(therapeutic use)
- Thrombolytic Therapy
(methods)
- Ticlopidine
(analogs & derivatives, therapeutic use)
- Treatment Outcome
|